The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial

IF 2.8 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Integrative Medicine Research Pub Date : 2023-03-01 DOI:10.1016/j.imr.2022.100914

Ji-Eun Lee , Hyung Won Kang , Sun-A Jung , So-Young Lee , Ju Yeon Kim , Da Eun Lee , Jin-Hyung Jeong , In Chul Jung , Eun Cho

{"title":"The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial","authors":"Ji-Eun Lee , Hyung Won Kang , Sun-A Jung , So-Young Lee , Ju Yeon Kim , Da Eun Lee , Jin-Hyung Jeong , In Chul Jung , Eun Cho","doi":"10.1016/j.imr.2022.100914","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Mild cognitive impairment (MCI), the early stage of dementia, requires effective intervention for symptom management and improving patients’ quality of life (QoL). Jujadokseo-hwan (JDH) is a Korean herbal medicine prescription used to improve MCI symptoms, such as memory deficit. This study evaluates the improvement in QoL through JDH. Alongside a clinical trial, it estimates the cost-effectiveness of JDH, compared to placebo, for MCI over 24 weeks.</p></div><div><h3>Methods</h3><p>Changes in QoL were measured using the EuroQol-5 Dimensions (EQ-5D) and Korean version QoL-Alzheimer's Disease (KQOL-AD). Direct medical and non-medical costs were surveyed and incremental cost-effectiveness ratios (ICER) per QALY for JDH were produced.</p></div><div><h3>Results</h3><p>In total, 64 patients were included in the economic evaluation (n = 35 in JDH, n = 29 in placebo). In the JDH group, EQ-5D and KQOL-AD improved by 0.020 (p = .318) and 3.40 (p = .011) over 24 weeks, respectively. In the placebo group, they increased by 0.001 (p=.920) and 1.07 (p=.130), respectively. The ICER was KRW 76,400,000 per QALY and KRW 108,000 per KQOL-AD for JDH, compared to the placebo group.</p></div><div><h3>Conclusion</h3><p>JDH is not considered a cost-effective treatment option compared with placebo; however, it positively affects QoL improvement in patients with MCI.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/eb/main.PMC9826841.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative Medicine Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213422022000816","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Mild cognitive impairment (MCI), the early stage of dementia, requires effective intervention for symptom management and improving patients’ quality of life (QoL). Jujadokseo-hwan (JDH) is a Korean herbal medicine prescription used to improve MCI symptoms, such as memory deficit. This study evaluates the improvement in QoL through JDH. Alongside a clinical trial, it estimates the cost-effectiveness of JDH, compared to placebo, for MCI over 24 weeks.

Methods

Changes in QoL were measured using the EuroQol-5 Dimensions (EQ-5D) and Korean version QoL-Alzheimer's Disease (KQOL-AD). Direct medical and non-medical costs were surveyed and incremental cost-effectiveness ratios (ICER) per QALY for JDH were produced.

Results

In total, 64 patients were included in the economic evaluation (n = 35 in JDH, n = 29 in placebo). In the JDH group, EQ-5D and KQOL-AD improved by 0.020 (p = .318) and 3.40 (p = .011) over 24 weeks, respectively. In the placebo group, they increased by 0.001 (p=.920) and 1.07 (p=.130), respectively. The ICER was KRW 76,400,000 per QALY and KRW 108,000 per KQOL-AD for JDH, compared to the placebo group.

Conclusion

JDH is not considered a cost-effective treatment option compared with placebo; however, it positively affects QoL improvement in patients with MCI.

查看原文本刊更多论文

草药(Jujadokseo-hwan)对轻度认知障碍患者生活质量的影响:随机对照试验的成本效益分析

背景轻度认知障碍(mild cognitive impairment, MCI)是早期痴呆，需要有效的干预来控制症状，提高患者的生活质量(QoL)。九加寿焕(JDH)是一种用于改善记忆障碍等轻度认知障碍症状的韩国草药处方。本研究通过JDH评估生活质量的改善。除了一项临床试验外，它还估计了与安慰剂相比，JDH在24周内治疗轻度认知损伤的成本效益。方法采用欧洲生活质量-5量表(EQ-5D)和韩版生活质量-阿尔茨海默病量表(KQOL-AD)测定生活质量的变化。调查了直接医疗费用和非医疗费用，并得出了JDH每个质量质量的增量成本效益比。结果共纳入64例患者进行经济评价(JDH组35例，安慰剂组29例)。在JDH组，EQ-5D和KQOL-AD在24周内分别提高了0.020 (p = .318)和3.40 (p = .011)。在安慰剂组，它们分别增加了0.001 (p= 0.920)和1.07 (p= 0.130)。与安慰剂组相比，JDH的ICER为每QALY 76,400,000韩元，每KQOL-AD 108,000韩元。结论与安慰剂相比，jdh不被认为是一种具有成本效益的治疗选择;然而，它对轻度认知障碍患者生活质量的改善有积极的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Integrative Medicine Research Medicine-Complementary and Alternative Medicine

CiteScore

6.50

自引率

2.90%

发文量

审稿时长

12 weeks

期刊介绍： Integrative Medicine Research (IMR) is a quarterly, peer-reviewed journal focused on scientific research for integrative medicine including traditional medicine (emphasis on acupuncture and herbal medicine), complementary and alternative medicine, and systems medicine. The journal includes papers on basic research, clinical research, methodology, theory, computational analysis and modelling, topical reviews, medical history, education and policy based on physiology, pathology, diagnosis and the systems approach in the field of integrative medicine.